SEC Tracker
Get the app

Atea Pharmaceuticals AVIR

Atea Pharmaceuticals reports Q3 2026 results and trial updates

Atea Pharmaceuticals (AVIR) filed an 8-K with the SEC on Nov 9, 2026, 4:17 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Phase 3 C-BEYOND trial met primary and secondary endpoints for BEM/RZR
  2. C-FORWARD trial topline results expected in early 2027
  3. Secured up to $200 million in non-dilutive funding from Hercules Capital

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Atea Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.